Kavigale AstraZeneca Pty Ltd
Product name
Kavigale
Sponsor
Accepted date
Sep-2024
Active ingredients
sipavibart
Proposed indication
Prevention of COVID-19 in adults and adolescents 12 years of age and older who have a weakened immune system (due to a medical condition or due to medicines that suppress the immune system)
Application type
A (new medicine)
Publication date
Sep-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.